TTC39A

Across TCGA pan-cancer cohorts, TTC39A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TTC39A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TTC39A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TTC39A is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where TTC39A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TTC39A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.818	<.001	11	view →
LSCC	Female	All	−0.819	<.001	9	view →
HNSC	All	IV	−1.109	<.001	8	view →
COAD	All	II,III,IV	−0.288	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TTC39A–CCRCC

Open the CCRCC breakdown →